[TAKEDA PHARMACEUTICAL] FY2026 Financial Results | Record High Sales and Profits | May 2026

Overview of Financial Performance

For the fiscal year ending March 2026, consolidated net sales amounted to a record 55,604 million yen (up 2.3% YoY), with profits significantly increasing driven by increased sales of overseas construction machinery and the effects of yen depreciation. Operating profit was 7,184 million yen (+11.2%), and net income attributable to owners of the parent was 5,596 million yen (+17.4%), maintaining a robust performance. Segment-wise, sales expansion overseas and proactive cost management led to an all-time high result.

Outlook and Impact on Shareholders

The earnings forecast for the fiscal year ending March 2027 anticipates some profit downside due to declining demand for domestic construction machinery and rising raw material costs, but sales are expected to remain firm supported by increased demand in the North American market. The annual dividend will be maintained at 72 yen, reflecting a commitment to shareholder return. Based on the medium-term vision, the company will continue expanding overseas operations and reducing costs, aiming for sustainable enhancement of corporate value.